Michael Schmitz
Stock Analyst at Guggenheim
(1.28)
# 3,436
Out of 4,761 analysts
15
Total ratings
42.86%
Success rate
-3.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $72 → $82 | $41.34 | +98.36% | 2 | Oct 28, 2024 | |
| MRUS Merus | Maintains: Buy | $93 → $111 | $47.37 | +134.33% | 2 | Oct 1, 2024 | |
| BPMC Blueprint Medicines | Maintains: Buy | $130 → $138 | $92.25 | +49.59% | 8 | Aug 2, 2024 | |
| ARVN Arvinas | Upgrades: Buy | $40 | $17.77 | +125.10% | 1 | Nov 20, 2023 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $1.42 | - | 1 | Jan 3, 2023 | |
| NOVA Sunnova Energy International | Initiates: Buy | $15 | $1.95 | +669.23% | 1 | Jan 6, 2020 |
Revolution Medicines
Oct 28, 2024
Maintains: Buy
Price Target: $72 → $82
Current: $41.34
Upside: +98.36%
Merus
Oct 1, 2024
Maintains: Buy
Price Target: $93 → $111
Current: $47.37
Upside: +134.33%
Blueprint Medicines
Aug 2, 2024
Maintains: Buy
Price Target: $130 → $138
Current: $92.25
Upside: +49.59%
Arvinas
Nov 20, 2023
Upgrades: Buy
Price Target: $40
Current: $17.77
Upside: +125.10%
Fate Therapeutics
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
Sunnova Energy International
Jan 6, 2020
Initiates: Buy
Price Target: $15
Current: $1.95
Upside: +669.23%